CLIA Waiver, Oral Fluid Claim Next For HHS-Backed OraQuick Rapid HIV Test
This article was originally published in The Gray Sheet
Executive Summary
OraSure and FDA are discussing a CLIA waiver protocol the company has submitted for its OraQuick rapid HIV diagnostic test, which gained premarket approval Nov. 7
You may also be interested in...
OraSure Targets HIV-1/2, Hepatitis Tests To Grow Business To $250 Mil.
OraSure is setting its sights on obtaining FDA approval of an OraQuick HIV-2 rapid oral fluid test, as well as licensing rights from Bio-Rad for the antibody patents, following approval of an HIV-1 version March 26
OraSure Targets HIV-1/2, Hepatitis Tests To Grow Business To $250 Mil.
OraSure is setting its sights on obtaining FDA approval of an OraQuick HIV-2 rapid oral fluid test, as well as licensing rights from Bio-Rad for the antibody patents, following approval of an HIV-1 version March 26
MedMira Three-Minute Rapid HIV Test Revealed Upon FDA Approval
Canadian firm MedMira will market its Reveal rapid HIV-1 test to U.S. hospitals and clinics through distributor Cardinal Health